Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$360.1m

Jasper Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Jasper Therapeutics has a total shareholder equity of $78.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $94.9M and $16.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$86.89m
EquityUS$78.44m
Total liabilitiesUS$16.45m
Total assetsUS$94.89m

Recent financial health updates

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Recent updates

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Oct 14
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Aug 12

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jun 19
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Financial Position Analysis

Short Term Liabilities: JSPR's short term assets ($88.9M) exceed its short term liabilities ($12.4M).

Long Term Liabilities: JSPR's short term assets ($88.9M) exceed its long term liabilities ($4.1M).


Debt to Equity History and Analysis

Debt Level: JSPR is debt free.

Reducing Debt: JSPR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: JSPR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: JSPR has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 33.1% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.